Furthermore, we show that KP372-1 was ten-fold more potent to kill NQO1-positive cancer cells (IC50: 0.017 μM vs. 2 μM) compared to other NQO1 bioactivatable drugs, such as β-lapachone (Figures 1E, F and Figures S1G, M) (21). This evidence concerns the gene NQO1 and cancer.